Difference between revisions of "Aldesleukin (Proleukin)"
Warner-admin (talk | contribs) m (Text replacement - "Category:Drug index" to "Category:Drugs") |
Warner-admin (talk | contribs) m (Text replacement - "[[Category:Renal cancer" to "[[Category:Renal_cell_carcinoma") |
||
| Line 35: | Line 35: | ||
[[Category:Neuroblastoma medications]] | [[Category:Neuroblastoma medications]] | ||
[[Category:Osteosarcoma medications]] | [[Category:Osteosarcoma medications]] | ||
| − | [[Category: | + | [[Category:Renal_cell_carcinoma medications]] |
[[Category:Drugs FDA approved in 1992]] | [[Category:Drugs FDA approved in 1992]] | ||
Revision as of 12:51, 30 July 2018
General information
Class/mechanism: Recombinant interleukin-2 which activates the immune system. Aldesleukin encourages growth of IL-2 dependent cells, triggers natural killer (NK) and lymphokine-activated killer (LAK) cell activity, induces production of interferon gamma, and increases lymphocyte cytotoxicity.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Aldesleukin (Proleukin) patient drug information (Chemocare)[4]
- Aldesleukin (Proleukin) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 5/5/1992: Initial FDA approval
Also known as
- Generic names: Interleukin-2, IL-2
- Brand names: Macrolin, Proleukin